[
  {
    "ts": null,
    "headline": "INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma",
    "summary": "Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.",
    "url": "https://finnhub.io/api/news?id=904c717311e7b85ff59f7da15393922af3c1ebdee7932d54d089e066d817a346",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767712740,
      "headline": "INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma",
      "id": 138002097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.",
      "url": "https://finnhub.io/api/news?id=904c717311e7b85ff59f7da15393922af3c1ebdee7932d54d089e066d817a346"
    }
  }
]